AbbVie Inc. (ABBV)

NYSE: ABBV · IEX Real-Time Price · USD
142.60
+0.52 (0.37%)
At close: Aug 12, 2022 4:03 PM
142.35
-0.25 (-0.18%)
After-hours: Aug 12, 2022 7:59 PM EDT
0.37%
Market Cap 252.13B
Revenue (ttm) 57.35B
Net Income (ttm) 12.64B
Shares Out 1.77B
EPS (ttm) 7.07
PE Ratio 20.17
Forward PE 9.89
Dividend $5.53 (3.88%)
Ex-Dividend Date Jul 14, 2022
Volume 4,902,764
Open 141.89
Previous Close 142.08
Day's Range 140.27 - 143.02
52-Week Range 105.56 - 175.91
Beta 0.68
Analysts Buy
Price Target 165.90 (+16.3%)
Earnings Date Jul 29, 2022

About ABBV

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with ... [Read more...]

Industry Biotechnology
CEO Richard Gonzalez
Employees 50,000
Stock Exchange NYSE
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2021, AbbVie's revenue was $56.20 billion, an increase of 22.69% compared to the previous year's $45.80 billion. Earnings were $11.54 billion, an increase of 150.04%.

Financial Statements

Analyst Forecast

According to 31 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is 165.9, which is an increase of 16.34% from the latest price.

Price Target
$165.9
(16.34% upside)
Analyst Consensus: Buy
Stock Forecasts

News

How the Inflation Reduction Act will affect Medicare

Yahoo Finance's Anjalee Khemlani breaks down the impacts the Inflation Reduction Act could have on Medicare enrollees should Congress pass it.

Other symbols: JNJMRKPFEUNH

10 defensive stocks that can also provide you with growth and dividends over the long term

The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.

7 Blue-Chip Stocks That Will Survive 2022

Buying high-quality blue-chip stocks in a bear market could be a solid path to generating lucrative long-term returns. Blue-chip stocks are typically large-cap businesses in the mature stage of their bu...

Other symbols: BDXCIDDJPMMMMPFE

The 7 Most Undervalued Value Stocks to Buy Now

Value stocks are always a sensible class of equities to consider as an investment. It's all about finding stocks that are believed to be trading below where they should be based on fundamental metrics.

Other symbols: ALLYINTCMETAURIVLOWMT

3 Unstoppable Stocks That Don't Care About the Bear Market

When the market is falling, this trio keeps rising.

Other symbols: AZNBMY

3 Unstoppable Dividend Stocks to Buy in August

Income investors have a lot to like about these stocks.

Other symbols: BMYPFE

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

3 Reasons Why AbbVie Stock Could Be Approaching a Make or Break Moment

It won't be able to rely on Humira for growth for much longer.

What's Happening With AbbVie Stock?

AbbVie stock (NYSE: ABBV) reported its Q2 results last week, with revenue falling short and earnings above the street estimates.

FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition

JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION IRVINE, Calif. , Aug. 3, 2022 /PRNewswire/ -- Today, Allergan Aestheti...

Medicare Drug Pricing Changes Could Be Coming: Time to Ditch Pharma Stocks?

Big pharma executives are worried that one part of the Inflation Reduction Act will reduce their companies' profits.

Other symbols: MRKPFE

Why AbbVie Is A Top 25 Dividend Giant

AbbVie has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $30.38B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 4.02% yield

Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines...

TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical compan...

3 Dividend Aristocrats to Buy in August

These stocks have reliable dividends and strong underlying businesses.

Other symbols: ABTPEP

Earn $300 in Quarterly Retirement Dividends With 3 Easy Steps

With the market down close to 20% this year, passive income has become more important.

Other symbols: TROW

3 Stocks We Think Could Beat the Market in the Second Half of 2022

These stocks share several things in common.

Other symbols: AZNJNJ

ABBVIE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate ...

NEW ORLEANS , July 29, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

Why AbbVie Stock Is Tanking Today

The drugmaker's Q2 results aren't sitting well with shareholders today.

AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag

AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales.

ABBV Stock Slips as AbbVie Faces Opioid Lawsuits

AbbVie (NYSE: ABBV ) recently published the company's second-quarter 2022 financial data. The results weren't very different from what Wall Street's analysts had expected.

AbbVie (ABBV) Q2 Earnings Beat Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 1.81% and 0.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AbbVie Ekes Out Narrow Second-Quarter Beat, Confirms 2022 Outlook

AbbVie narrowly topped second-quarter expectations Friday and reaffirmed its earnings outlook. But AbbVie stock fell early.

AbbVie reports an increase in second-quarter revenue, led by sales of Humira

Shares of AbbVie Inc. ABBV, -0.93% were down 1.3% in premarket trading on Friday though the company met earnings and revenue expectations for the second quarter of the year. AbbVie had earnings of $924 ...

AbbVie sets aside $2 billion to settle U.S. opioid claims

AbbVie Inc has set aside about $2 billion to resolve thousands of lawsuits against its Allergan unit over the marketing of its opioid products, the company said on Friday.

AbbVie Reports Second-Quarter 2022 Financial Results

Reports Second-Quarter Diluted EPS of $0.51 on a GAAP Basis, an Increase of 21.4 Percent; Adjusted Diluted EPS of $3.37, an Increase of 11.2 Percent; These Results Include an Unfavorable Impact of $0.14...